Global Pfizer Licensing Deal
Medicus Pharma secures a global licensing deal with Pfizer for CD228V oncology treatment.
Anonymous
Key Points
1
CD228V targets melanotransferrin (CD228), a cell-surface glycoprotein encoded by the MF12 gene that is highly expressed on melanoma cells (and also present in other solid tumors), underscoring the program’s biology and rationale for targeting this antigen.
2
Pfizer retains oversight rights and has the option to fund development after the first pivotal trial, including reviewing budgets and receiving progress reports, with any additional funding governed by a separate definitive agreement.
3
The deal contemplates tiered royalties on annual net sales in the low double-digit range and milestone payments that could exceed $1 billion, plus Pfizer’s right to a portion of proceeds if the program is sublicensed or involved in strategic transactions (including in a change of control).
4
The agreement is effective September 2, 2026, and comes amid Pfizer’s broader strategy to reallocate Seagen-derived ADC assets, with CD228V representing Medicus’s expanded role in precision oncology within Pfizer’s ecosystem.
Medicus Pharma has secured exclusive global rights to develop and commercialize Pfizer's CD228V, an experimental cancer drug targeting melanoma and other solid tumors. The deal includes a $12 million upfront payment, another $15 million due next year, and potential milestone payments exceeding $1 billion, Benzinga reported. Medicus will control development, manufacturing, and commercialization while Pfizer retains the right to fund later-stage trials and earn royalties on future sales.
Why Pfizer Handed Off This Cancer Drug
CD228V is an antibody-drug conjugate — a precision cancer therapy that uses an antibody to deliver toxic drugs directly to tumor cells. Fierce Biotech noted Pfizer obtained the drug through its 2023 acquisition of Seagen, a biotech company known for ADC expertise. Pfizer has since reorganized its ADC pipeline, offloading certain programs like CD228V to focus resources elsewhere.
The drug targets melanotransferrin (CD228), a protein highly expressed on melanoma cells and other solid tumors, according to Kalkinemedia. This specific targeting gives CD228V a clear biological rationale, making it attractive to Medicus as it expands into precision oncology.
Medicus Gains Control While Pfizer Stays Invested
Medicus takes the lead on all development, manufacturing, and sales decisions. Kalkinemedia reported Pfizer will contribute $2 million to CD228V development and may fund all later-stage trials after the first pivotal study. Pfizer also retains oversight rights and receives progress reports.
Pfizer's upside comes through milestones potentially exceeding $1 billion and tiered royalties on net sales, Biopharm International stated. Pfizer also gets a share of proceeds if Medicus sublicenses the drug or undergoes a change of control. The deal took effect around September 2, 2026.
A Major Milestone for Medicus in Oncology
The agreement marks a significant step for Medicus, expanding its footprint in oncology while partnering with a pharma giant. Kalkinemedia highlighted the deal as a turning point, giving Medicus a late-stage clinical program with clear commercial potential. The dual focus on melanoma and other solid tumors opens multiple development paths.
For Pfizer, the arrangement allows the company to maintain financial upside through royalties and milestones without bearing full development costs. This structure reflects Pfizer's broader pivot toward partnering and licensing arrangements rather than retaining early-stage programs internally, freeing capital for other priorities.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
1
Reach
14
A
AnonymousAuthor
